Johnson & Johnson’s prostate cancer drug Zytiga improved survival in patients who have not received chemotherapy in a late-stage study.
An independent data monitoring committee recommended that patients receiving a placebo in the trial be offered treatment with Zytiga, the company said in a statement.
Thursday’s data sent shares of Medivation Inc, which is also developing a prostate cancer pill that works by targeting the same hormone that Zytiga targets, up 9 percent.
However, shares of Dendreon Corp fell 16 percent. Dendreon makes a prostate cancer vaccine, Provenge, that has a different mechanism of action.
(Reporting by Kavyanjali Kaushik and Esha Dey in Bangalore; Editing by Gopakumar Warrier)